Literature DB >> 23856992

miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.

Tianzhu Qiu1, Li Zhou, Tongshan Wang, Jing Xu, Jian Wang, Wenjiao Chen, Xin Zhou, Zebo Huang, Wei Zhu, Yongqian Shu, Ping Liu.   

Abstract

Drug resistance is one of the leading causes of chemotherapy failure in cancer treatment. MicroRNAs (miRNAs or miRs) are short non-coding RNA molecules that post-transcriptionally regulate gene expression and play a critical role in diverse biological processes. In this study, we report that miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin. The expression of miR-503 was decreased in the cisplatin-resistant non-small cell lung cancer cells, A549/CDDP, compared with the parental A549 cells. The overexpression of miR-503 sensitized the A549/CDDP cells to cisplatin, whereas the inhibition of miR-503 in the A549 cells increased resistance to cisplatin. Mechanistically, miR-503 specifically targeted Bcl-2, an anti-apoptotic protein upregulated in the A549/CDDP cells. The ectopic expression of miR-503 reduced the Bcl-2 protein level and sensitized the A549/CDDP cells to cisplatin-induced apoptosis. Taken together, our results suggest that miR-503 regulates cell apoptosis, at least in part by targeting Bcl-2, and thus modulates the resistance of non-small cell lung cancer cells to cisplatin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23856992     DOI: 10.3892/ijmm.2013.1439

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  37 in total

Review 1.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

Review 2.  Therapeutic prospects of microRNAs in cancer treatment through nanotechnology.

Authors:  Rajendra Awasthi; Michael John Rathbone; Philip Michael Hansbro; Mary Bebawy; Kamal Dua
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

3.  MicroRNA-503 serves an oncogenic role in retinoblastoma progression by directly targeting PTPN12.

Authors:  Yang Cheng; Wei Liu
Journal:  Exp Ther Med       Date:  2019-07-19       Impact factor: 2.447

4.  MicroRNA-205 suppresses proliferation and promotes apoptosis in laryngeal squamous cell carcinoma.

Authors:  Linli Tian; Jiarui Zhang; Jingchun Ge; Hui Xiao; Jianguang Lu; Songbin Fu; Ming Liu; Yanan Sun
Journal:  Med Oncol       Date:  2013-12-03       Impact factor: 3.064

5.  microRNA-503 suppresses the migration, proliferation and colony formation of prostate cancer cells by targeting tumor protein D52 like 2.

Authors:  Yuhua Chi; Feng Ding; Wenjie Zhang; Lifa Du
Journal:  Exp Ther Med       Date:  2017-10-30       Impact factor: 2.447

6.  Anticancer function of α-solanine in lung adenocarcinoma cells by inducing microRNA-138 expression.

Authors:  Furui Zhang; Rui Yang; Guojun Zhang; Ruirui Cheng; Yong Bai; Huasi Zhao; Xinhua Lu; Hui Li; Shanshan Chen; Juan Li; Shujun Wu; Ping Li; Xiaonan Chen; Qianqian Sun; Guoqiang Zhao
Journal:  Tumour Biol       Date:  2015-12-02

Review 7.  MicroRNAs in pulmonary arterial hypertension.

Authors:  Guofei Zhou; Tianji Chen; J Usha Raj
Journal:  Am J Respir Cell Mol Biol       Date:  2015-02       Impact factor: 6.914

8.  MicroRNA 192 regulates chemo-resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl-2.

Authors:  Jun Cao; Yang He; Hong-Qiang Liu; Sai-Bo Wang; Bao-Cheng Zhao; Ying-Sheng Cheng
Journal:  Int J Clin Exp Med       Date:  2015-08-15

9.  Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer.

Authors:  Nicolas Bovy; Benoît Blomme; Pierre Frères; Stella Dederen; Olivier Nivelles; Michelle Lion; Oriane Carnet; Joseph A Martial; Agnès Noël; Marc Thiry; Guy Jérusalem; Claire Josse; Vincent Bours; Sébastien P Tabruyn; Ingrid Struman
Journal:  Oncotarget       Date:  2015-04-30

10.  MicroRNA-503 acts as a tumor suppressor in glioblastoma for multiple antitumor effects by targeting IGF-1R.

Authors:  Yingying Zhang; Xiong Chen; Haiwei Lian; Jianmiao Liu; Beiyan Zhou; Song Han; Biwen Peng; Jun Yin; Wanhong Liu; Xiaohua He
Journal:  Oncol Rep       Date:  2013-12-30       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.